Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Bristol-Myers Squibb163 enrolled

Overview

The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US

Study Type

OBSERVATIONAL

Enrollment

163

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

MavacamtenDRUG

According to the product label

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years at index date * Prescription of mavacamten for the treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) * ≥ 4 weeks of follow-up after prescription of mavacamten Exclusion Criteria: * Data collection as part of a clinical trial during the study period * Current participation in a myosin inhibitor clinical trial

Locations (1)

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Participant New York Heart Association (NYHA) functional class

Time frame: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks

Participant echocardiogram measurements: Left ventricular outflow tract (LVOT) gradient results at rest, Valsalva and post-exercise (if available)

Time frame: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks

Participant echocardiogram measurements: Left ventricular ejection fraction (LVEF) percentage

Time frame: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks

Participant echocardiogram measurements: Maximum left ventricular wall thickness

Time frame: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks

Participant age

Time frame: Baseline

Participant gender

Time frame: Baseline

Participant race

Time frame: Baseline

Participant ethnicity

Time frame: Baseline

Participant insurance coverage

Time frame: Baseline

Participant Body Mass Index

Time frame: Baseline

Participant blood pressure

Time frame: Baseline

Participant heart rate

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.